Search 

Pharmidex is a CRO founded in 2002 specialising in providing cost effective, high quality experimental ADMET/PK data. Focusing on bioanalysis, CNS drug discovery, in vitro ADMET, in vivo pharmacokinetics, metabolite identification and toxicology we have been able to deliver high levels of customer satisfaction.

Pharmidex operates with a “part of your team” mentality and understands the importance of making time to discuss studies with clients.

PHASTAR is a specialist CRO offering statistical consultancy, clinical trial reporting (including data management) and medical writing services, by providing expert consultants and delivering in-house projects.

Every project PHASTAR undertakes is supervised on methodology and utilises internal processes designed to ensure optimal quality. We are headquartered in London with 7 offices globally across four continents, and the largest statistical CRO group in Europe.

Propath is a leader in Europe for histopathology and molecular pathology.  As a GLP and GCP compliant facility, our experience of regulatory and research studies spans over 30 years.

Quay Pharma is one of the world’s leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing, MHRA and FDA inspected and approved.

Based at St Georges University of London, Richmond Pharmacology Limited is one of 14 MHRA accredited UK phase one units specialising in early phase Adaptive Studies (including First-In-Human), Cardiac Safety/Intensive ECG/Thorough QT studies, Ethnic Bridging studies and Patient Studies.

Our Principal Investigators offer peer-to-peer advice, intelligent protocol design and development and expert know-how for global regulatory requirements.Our streamlined methods ensure we deliver each milestone right on cue, with no extensions and no extra cost.

Sciad Communications is a leading marketing and PR consultancy working in Health, Science and Tech.Our aim is to make our clients more successful. By integrating Brand, PR and Digital Marketing we build reputations, accelerate growth and attract investment. We have an excellent track record in developing communications programmes for our clients, helping them to stay ahead of their competitors and become market leaders.

Scottish Development International is a government-funded organisation which provides access to key Scottish product and service companies in the life sciences, together with research and clinical expertise from Scottish Universities and Research Institutes and financial support programs to support your development.

Scotland’s life sciences sector consists of over 650 organisations employing over 32,500 people and is one of the world's leading centres for stem cell research and regenerative medicine. Scotland has built a reputation as one of Europe's leading locations for the development of new tools and technologies, as well as the clinical assessment of new cell-based therapies. These strengths are based on the connectivity of the translational, clinical, analytical and regulatory support mechanisms.

The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.

We are based at Cheadle Royal Business Park, a centre of scientific excellence in the North of England.

By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.

Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.

Strategy > Design > Data > Interpretation > Execution

• Consultancy
• Physicochemical characterisation and preformulation studies
• Solid form selection including polymorphs, salts and co-crystals
• Preclinical safety study formulation development for challenging molecules
• First-time-in-clinic and later phase / commercial formulation development
• Enabling formulations and specialist drug delivery technology selection
• Preclinical DMPK
• Clinical pharmacokinetics and drug absorption including modeling
• Due diligence, competitor analysis and technology opportunity assessments
• Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards

Routes of administration and technology areas we cover:

Oral

• Immediate release
• Modified release
• Oral poorly solubles

Standard Injectables 

Complex Injectables

• Poorly soluble IV
• Depot
• Targeted

Nasal and Inhaled

Selcia is a leading global CRO specialising in 14C GMP radiolabelled API for clinical trials and in 14C custom radiolabelling for DMPK, dermal penetration and environmental fate studies.

Selcia offers the full range of drug discovery services; integrated drug discovery, assay development, medicinal chemistry and ADME. With specialist expertise in macrocycles, natural products and their simplification and optimisation for drug use. Selcia has a unique peptidyl prolyl isomerase (PPIase) inhibitor screening platform.

To support regulatory submissions, Selcia offers GLP analysis; including GLP NMR (500MHz), mass spectrometry, HPLC (analytical and preparative) and specialised purification capabilities from analytical (µg) to multi-100g scale.

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.